Alteplase Treatment in Acute Stroke: Incorporating Food and Drug Administration Prescribing Information into Existing Acute Stroke Management Guide

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Despite strong evidence that intravenous tissue plasminogen activator (tPA) improves outcomes in acute ischemic stroke patients, its use in clinical practice remains modest. Complex eligibility criteria have been postulated as barriers to greater utilization. Further complicating this has been multiple guidelines and prescribing labels that have been published since first being approved for use in 1996. In this review, several warning and exclusion criteria for tPA in acute ischemic stroke are reviewed with the goal of providing readers a nuanced understanding of historical context and available evidence to make informed decision.

Original languageEnglish (US)
Article number53
JournalCurrent Atherosclerosis Reports
Volume18
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Drug Prescriptions
Tissue Plasminogen Activator
United States Food and Drug Administration
Stroke
Guidelines
Therapeutics

Keywords

  • Alteplase
  • Food and Drug Administration
  • Guidelines
  • Ischemic stroke
  • Tissue plasminogen activator

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{725368e86b1948bc9d9b72950104b32f,
title = "Alteplase Treatment in Acute Stroke: Incorporating Food and Drug Administration Prescribing Information into Existing Acute Stroke Management Guide",
abstract = "Despite strong evidence that intravenous tissue plasminogen activator (tPA) improves outcomes in acute ischemic stroke patients, its use in clinical practice remains modest. Complex eligibility criteria have been postulated as barriers to greater utilization. Further complicating this has been multiple guidelines and prescribing labels that have been published since first being approved for use in 1996. In this review, several warning and exclusion criteria for tPA in acute ischemic stroke are reviewed with the goal of providing readers a nuanced understanding of historical context and available evidence to make informed decision.",
keywords = "Alteplase, Food and Drug Administration, Guidelines, Ischemic stroke, Tissue plasminogen activator",
author = "Demaerschalk, {Bart M}",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s11883-016-0602-5",
language = "English (US)",
volume = "18",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "8",

}

TY - JOUR

T1 - Alteplase Treatment in Acute Stroke

T2 - Incorporating Food and Drug Administration Prescribing Information into Existing Acute Stroke Management Guide

AU - Demaerschalk, Bart M

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Despite strong evidence that intravenous tissue plasminogen activator (tPA) improves outcomes in acute ischemic stroke patients, its use in clinical practice remains modest. Complex eligibility criteria have been postulated as barriers to greater utilization. Further complicating this has been multiple guidelines and prescribing labels that have been published since first being approved for use in 1996. In this review, several warning and exclusion criteria for tPA in acute ischemic stroke are reviewed with the goal of providing readers a nuanced understanding of historical context and available evidence to make informed decision.

AB - Despite strong evidence that intravenous tissue plasminogen activator (tPA) improves outcomes in acute ischemic stroke patients, its use in clinical practice remains modest. Complex eligibility criteria have been postulated as barriers to greater utilization. Further complicating this has been multiple guidelines and prescribing labels that have been published since first being approved for use in 1996. In this review, several warning and exclusion criteria for tPA in acute ischemic stroke are reviewed with the goal of providing readers a nuanced understanding of historical context and available evidence to make informed decision.

KW - Alteplase

KW - Food and Drug Administration

KW - Guidelines

KW - Ischemic stroke

KW - Tissue plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=84977623896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977623896&partnerID=8YFLogxK

U2 - 10.1007/s11883-016-0602-5

DO - 10.1007/s11883-016-0602-5

M3 - Review article

C2 - 27363696

AN - SCOPUS:84977623896

VL - 18

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 8

M1 - 53

ER -